Battle of the Biotech Unicorns: CureVac vs. Moderna

Ingmar Hoerr and Stephane Bancel are the founders and CEOs of CureVac and Moderna, two biotech unicorns pioneering mRNA therapy. In this interview with Clara, they talk about their companies, their relationship and a future where medicines will be driven by information.

The idea of messenger RNA as a therapy is simple but brilliant: instead of giving a protein to a patient, you give their body the instructions to produce its own.

CureVac, founded in 2000, was the first company to try to turn mRNA into a commercial therapy. Although the path was not easy, the German company has raised over €450M and is part of the global unicorn club with a valuation of €1.4Bn.

Across the Atlantic, Moderna Therapeutics, though founded much more recently in 2011, has grown very rapidly, raising $1.2Bn and reaching a $4.7Bn valuation.
Find all the biotech news in EU http://labiotech.eu/

About Labiotech.eu:
Labiotech.eu is the leading digital media covering the European Biotech industry. Over 75,000 monthly visitors use it to keep an eye on the business and innovations in biotechnology. Hope you'll enjoy reading our stories!

Facebook: https://www.facebook.com/Labiotech.eu
Twitter: https://twitter.com/Labiotech_eu
Linkedin: https://www.linkedin.com/company/labi...
Instagram: https://www.instagram.com/labiotech.eu
Meetup:https://www.meetup.com/Labiotech-Meetup/

#digitalmedia #biotech #mRNAtherapy

Видео Battle of the Biotech Unicorns: CureVac vs. Moderna канала Labiotech.eu